Phase 3 MorphoSys acquired by Novartis for US$3.4 BillionMarch 22, 2024 - Small Molecule Phase 3 cancer company MorphoSys has been acquired by Novartis for US$3.4 Billion. MorhoSys announced today the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the proposed acquisition of MorphoSys by Novartis AG ("Novartis"), following the expiration of the HSR Act waiting period. MorphoSys previously also announced the receipt of antitrust clearance in Germany and Austria. As a result, the proposed acquisition of MorphoSys by Novartis has now received all mandatory regulatory approvals.
On February 5, 2024, MorphoSys announced the intention of Novartis to submit a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares at an offer price of € 68.00 per share in cash (the "Takeover Offer"), representing a total equity value of € 2.7 billion. The offer document of the Takeover Offer is expected to be published by Novartis in April 2024 in accordance with the provisions of the German Securities Acquisition and Takeover Act, after the German Federal Financial Supervisory Authority ("BaFin") has approved the publication. Once the offer document is published by Novartis, the acceptance period for MorphoSys shareholders to tender their shares will begin. The Takeover Offer will require a minimum acceptance threshold of 65% of MorphoSys' share capital, among other customary closing conditions.
MorphoSys and Novartis continue to expect the closing of the Takeover Offer to take place in the first half of 2024.
https://www.morningstar.com/news/accesswire/845738msn/morphosys-announces-us-antitrust-clearance-of-proposed-acquisition-by-novartis-under-hsr-act